Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions

被引：5

作者：

Desikan, RK ^{[1
]}

Jagannath, S ^{[1
]}

机构：

[1] St Vincents Comprehens Canc Ctr, New York, NY 10011 USA

来源：

SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 06期

关键词：

D O I：

10.1053/sonc.2001.28613

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：593 / 596

页数：4

共 25 条

[1]

Badros A, 2000, BLOOD, V96, p285B

[2] Total therapy with tandem transplants for newly diagnosed multiple myeloma [J].

Barlogie, B ;

Jagannath, S ;

Desikan, KR ;

Mattox, S ;

Vesole, D ;

Siegel, D ;

Tricot, G ;

Munshi, N ;

Fassas, A ;

Singhal, S ;

Mehta, J ;

Anaissie, E ;

Dhodapkar, D ;

Naucke, S ;

Cromer, J ;

Sawyer, J ;

Epstein, J ;

Spoon, D ;

Ayers, D ;

Cheson, B ;

Crowley, J .

BLOOD, 1999, 93 (01) :55-65

[3]

Bellamy WT, 1999, CANCER RES, V59, P728

[4]

CHAPON F, 1985, REV NEUROL-FRANCE, V141, P719

[5] THALIDOMIDE NEUROTOXICITY [J].

CLEMMENSEN, OJ ;

OLSEN, PZ ;

ANDERSEN, KE .

ARCHIVES OF DERMATOLOGY, 1984, 120 (03) :338-341

[6] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[7]

Desikan R, 1999, BLOOD, V94, p603A

[8] Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade [J].

Geitz, H ;

Handt, S ;

Zwingenberger, K .

IMMUNOPHARMACOLOGY, 1996, 31 (2-3) :213-221

[9]

HARLAND CC, 1995, EUR J CLIN PHARMACOL, V49, P1

[10] Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy [J].

Hideshima, T ;

Chauhan, D ;

Shima, Y ;

Raje, N ;

Davies, FE ;

Tai, YT ;

Treon, SP ;

Lin, B ;

Schlossman, RL ;

Richardson, P ;

Muller, G ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2000, 96 (09) :2943-2950

← 1 2 3 →